CN113908173A - Composition for reducing uric acid and preparation method thereof - Google Patents
Composition for reducing uric acid and preparation method thereof Download PDFInfo
- Publication number
- CN113908173A CN113908173A CN202010665328.0A CN202010665328A CN113908173A CN 113908173 A CN113908173 A CN 113908173A CN 202010665328 A CN202010665328 A CN 202010665328A CN 113908173 A CN113908173 A CN 113908173A
- Authority
- CN
- China
- Prior art keywords
- parts
- sodium
- uric acid
- composition
- dihydrogen phosphate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 title claims abstract description 44
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 title claims abstract description 44
- 229940116269 uric acid Drugs 0.000 title claims abstract description 44
- 239000000203 mixture Substances 0.000 title claims abstract description 35
- 238000002360 preparation method Methods 0.000 title abstract description 5
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims abstract description 51
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims abstract description 38
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims abstract description 38
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims abstract description 34
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims abstract description 19
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims abstract description 19
- 229930006000 Sucrose Natural products 0.000 claims abstract description 19
- 229910021538 borax Inorganic materials 0.000 claims abstract description 19
- HEBKCHPVOIAQTA-NGQZWQHPSA-N d-xylitol Chemical compound OC[C@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-NGQZWQHPSA-N 0.000 claims abstract description 19
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 claims abstract description 19
- UQGFMSUEHSUPRD-UHFFFAOYSA-N disodium;3,7-dioxido-2,4,6,8,9-pentaoxa-1,3,5,7-tetraborabicyclo[3.3.1]nonane Chemical compound [Na+].[Na+].O1B([O-])OB2OB([O-])OB1O2 UQGFMSUEHSUPRD-UHFFFAOYSA-N 0.000 claims abstract description 19
- 239000008103 glucose Substances 0.000 claims abstract description 19
- 229910000402 monopotassium phosphate Inorganic materials 0.000 claims abstract description 19
- 235000019796 monopotassium phosphate Nutrition 0.000 claims abstract description 19
- 229910000403 monosodium phosphate Inorganic materials 0.000 claims abstract description 19
- 235000019799 monosodium phosphate Nutrition 0.000 claims abstract description 19
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 claims abstract description 19
- 239000001103 potassium chloride Substances 0.000 claims abstract description 19
- 235000011164 potassium chloride Nutrition 0.000 claims abstract description 19
- 229910000029 sodium carbonate Inorganic materials 0.000 claims abstract description 19
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 claims abstract description 19
- 239000004328 sodium tetraborate Substances 0.000 claims abstract description 19
- 235000010339 sodium tetraborate Nutrition 0.000 claims abstract description 19
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 claims abstract description 19
- 235000019345 sodium thiosulphate Nutrition 0.000 claims abstract description 19
- 239000005720 sucrose Substances 0.000 claims abstract description 19
- 229910000503 Na-aluminosilicate Inorganic materials 0.000 claims abstract description 17
- 239000000377 silicon dioxide Substances 0.000 claims abstract description 17
- 235000012239 silicon dioxide Nutrition 0.000 claims abstract description 17
- 239000000429 sodium aluminium silicate Substances 0.000 claims abstract description 17
- 235000012217 sodium aluminium silicate Nutrition 0.000 claims abstract description 17
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 claims abstract description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 17
- 239000008213 purified water Substances 0.000 claims abstract description 16
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 36
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 36
- 239000000463 material Substances 0.000 claims description 24
- 229910000027 potassium carbonate Inorganic materials 0.000 claims description 18
- 239000011780 sodium chloride Substances 0.000 claims description 18
- 238000000034 method Methods 0.000 claims description 11
- 201000005569 Gout Diseases 0.000 abstract description 5
- 230000000694 effects Effects 0.000 abstract description 5
- 208000024891 symptom Diseases 0.000 abstract description 5
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 abstract 1
- 235000017550 sodium carbonate Nutrition 0.000 abstract 1
- 235000011121 sodium hydroxide Nutrition 0.000 abstract 1
- 201000001431 Hyperuricemia Diseases 0.000 description 10
- 239000003814 drug Substances 0.000 description 8
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- YBMRDBCBODYGJE-UHFFFAOYSA-N germanium dioxide Chemical compound O=[Ge]=O YBMRDBCBODYGJE-UHFFFAOYSA-N 0.000 description 4
- 229940079593 drug Drugs 0.000 description 3
- 235000006694 eating habits Nutrition 0.000 description 3
- 230000029142 excretion Effects 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 208000006820 Arthralgia Diseases 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 239000004111 Potassium silicate Substances 0.000 description 2
- 239000004115 Sodium Silicate Substances 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000035622 drinking Effects 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 229940119177 germanium dioxide Drugs 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 231100000915 pathological change Toxicity 0.000 description 2
- 230000036285 pathological change Effects 0.000 description 2
- 235000019353 potassium silicate Nutrition 0.000 description 2
- 229910052913 potassium silicate Inorganic materials 0.000 description 2
- NNHHDJVEYQHLHG-UHFFFAOYSA-N potassium silicate Chemical compound [K+].[K+].[O-][Si]([O-])=O NNHHDJVEYQHLHG-UHFFFAOYSA-N 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000011684 sodium molybdate Substances 0.000 description 2
- 235000015393 sodium molybdate Nutrition 0.000 description 2
- TVXXNOYZHKPKGW-UHFFFAOYSA-N sodium molybdate (anhydrous) Chemical compound [Na+].[Na+].[O-][Mo]([O-])(=O)=O TVXXNOYZHKPKGW-UHFFFAOYSA-N 0.000 description 2
- NTHWMYGWWRZVTN-UHFFFAOYSA-N sodium silicate Chemical compound [Na+].[Na+].[O-][Si]([O-])=O NTHWMYGWWRZVTN-UHFFFAOYSA-N 0.000 description 2
- 229910052911 sodium silicate Inorganic materials 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010018634 Gouty Arthritis Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 208000000913 Kidney Calculi Diseases 0.000 description 1
- 206010029148 Nephrolithiasis Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 206010038419 Renal colic Diseases 0.000 description 1
- 229940083914 URAT1 inhibitor Drugs 0.000 description 1
- 108010093894 Xanthine oxidase Proteins 0.000 description 1
- 102100033220 Xanthine oxidase Human genes 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 1
- 229960003459 allopurinol Drugs 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 235000012055 fruits and vegetables Nutrition 0.000 description 1
- 208000006750 hematuria Diseases 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 210000001503 joint Anatomy 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 231100000989 no adverse effect Toxicity 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 159000000000 sodium salts Chemical group 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 239000003064 xanthine oxidase inhibitor Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/30—Foods or foodstuffs containing additives; Preparation or treatment thereof containing carbohydrate syrups; containing sugars; containing sugar alcohols, e.g. xylitol; containing starch hydrolysates, e.g. dextrin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7016—Disaccharides, e.g. lactose, lactulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/22—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/42—Phosphorus; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Mycology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to a composition for reducing uric acid and a preparation method thereof, wherein the composition is prepared from the following components: silicon dioxide, sodium aluminosilicate, disodium hydrogen phosphate, sodium dihydrogen phosphate, potassium dihydrogen phosphate, sodium carbonate, potassium chloride, sodium hydroxide, sodium tetraborate, sodium thiosulfate, xylo-oligosaccharide, sucrose, glucose and purified water. The composition for reducing uric acid, which is prepared by the invention, can be used for obviously reducing uric acid only by taking a small amount of the composition, can effectively relieve gout symptoms, is convenient and safe, and does not cause side effects on a human body.
Description
Technical Field
The invention relates to the field of foods and health-care products, in particular to a composition for reducing uric acid and a preparation method thereof.
Background
With the improvement of living standard and the change of eating habit, the incidence of hyperuricemia and gout is gradually increased. In clinical diagnosis of Hyperuricemia (HUA), male serum uric acid is more than 417 mu mol/L, and female serum uric acid is more than 357 mu mol/L, namely hyperuricemia. Hyperuricemia is a disease in which blood uric acid exceeds normal values due to purine metabolic disorders and/or uric acid excretion disorders, and does not clinically manifest any symptoms. When a human body is in a hyperuricemia state for a long time, uric acid is precipitated in joints, soft tissues, cartilages and kidneys in a sodium salt form to cause organ and tissue pathological changes of the human body, gout is caused, serious complications are caused, the symptoms comprise gouty arthritis, gouty kidney pathological changes, gouty kidney stones, gouty hypertension and the like, and patients have symptoms of arthralgia, renal colic or hematuria and the like. High uric acid may cause gout, and is also closely related to cardiovascular diseases, Diabetes (DM), hypertension, obesity, hyperlipidemia, chronic kidney diseases, and the like.
At present, the prevention aiming at the hyperuricemia generally controls the intake of high purine food and meat, increases the intake of fruits and vegetables, limits drinking and enhances sports, and for the existing symptoms, mainly depends on drug treatment, and the drugs for treating the hyperuricemia mainly comprise a plurality of types, namely xanthine oxidase inhibitors for inhibiting the generation of uric acid, URAT1 inhibitors for promoting the excretion of uric acid, uricoxidase for promoting the decomposition of uric acid, and other mechanisms for reducing uric acid.
However, most of the drugs currently under development often cause adverse side effects, such as that allopurinol of xanthine oxidase can cause fatal anaphylaxis in individual patients, etc.
Disclosure of Invention
The composition for reducing uric acid can obviously reduce uric acid in a human body, is convenient and safe, and cannot cause damage to the human body.
The invention is realized by the following steps: a composition for reducing uric acid is prepared from the following components in parts by mass:
300 parts of silicon dioxide, 500 parts of sodium aluminosilicate 200, 1500 parts of disodium hydrogen phosphate, 60-100 parts of sodium dihydrogen phosphate, 8-12 parts of potassium dihydrogen phosphate, 50-300 parts of sodium carbonate, 500 parts of potassium carbonate 100, 50-150 parts of potassium chloride, 5-10 parts of sodium chloride, 0.4-1.2 parts of sodium hydroxide, 10-15 parts of sodium tetraborate, 5-15 parts of sodium thiosulfate, 1500 parts of xylo-oligosaccharide 200, 2000 parts of sucrose 500, 500 parts of glucose 100 and 1200 parts of purified water.
The further optimization scheme is that the composition for reducing uric acid is prepared from the following components in parts by mass:
125 parts of silicon dioxide, 332 parts of sodium aluminosilicate, 1100 parts of disodium hydrogen phosphate, 70 parts of sodium dihydrogen phosphate, 9 parts of potassium dihydrogen phosphate, 225 parts of sodium carbonate, 185 parts of potassium carbonate, 78 parts of potassium chloride, 8 parts of sodium chloride, 0.6 part of sodium hydroxide, 12 parts of sodium tetraborate, 10 parts of sodium thiosulfate, 500 parts of xylo-oligosaccharide, 1500 parts of sucrose, 350 parts of glucose and 1000 parts of purified water.
A method for preparing a composition for reducing uric acid, comprising the steps of:
300 parts of silicon dioxide-containing material, 500 parts of sodium aluminosilicate-containing material, 1500 parts of disodium hydrogen phosphate-containing material, 60-100 parts of sodium dihydrogen phosphate, 8-12 parts of potassium dihydrogen phosphate, 50-300 parts of sodium carbonate, 500 parts of potassium carbonate-containing material, 50-150 parts of potassium chloride, 5-10 parts of sodium chloride, 0.4-1.2 parts of sodium hydroxide, 10-15 parts of sodium tetraborate, 5-15 parts of sodium thiosulfate, 1500 parts of xylo-oligosaccharide-containing material, 500 parts of sucrose-containing material and 500 parts of glucose-containing material are gradually dissolved in 1200 parts of 800-containing material at the temperature of 60-80 ℃ and stirred for 150 minutes to form gel, and then placed at the temperature of 25-35 ℃ for more than 48 hours for later use.
In a further optimized scheme, the preparation method of the composition for reducing uric acid comprises the following steps:
125 parts of silicon dioxide, 332 parts of sodium aluminosilicate, 1100 parts of disodium hydrogen phosphate, 70 parts of sodium dihydrogen phosphate, 9 parts of potassium dihydrogen phosphate, 225 parts of sodium carbonate, 185 parts of potassium carbonate, 78 parts of potassium chloride, 8 parts of sodium chloride, 0.6 part of sodium hydroxide, 12 parts of sodium tetraborate, 10 parts of sodium thiosulfate, 500 parts of xylo-oligosaccharide, 1500 parts of sucrose and 350 parts of glucose are gradually dissolved in 1000 parts of purified water at 60 ℃ and stirred for 120 minutes to form gel, and the gel is placed for more than 48 hours at 30 ℃ for later use.
The composition for reducing uric acid prepared by the invention has the following advantages: the composition for reducing uric acid, which is prepared by the invention, reasonably combines various trace elements necessary for a human body, regulates the cellular metabolism, acid-base balance and ion balance of the human body, improves the digestion and absorption of the human body, and finally achieves the purposes of promoting purine absorption and reducing blood uric acid.
The invention has low cost, can achieve the effect only by using a small amount, and is convenient to carry and use.
Detailed Description
The present invention will be described in detail with reference to specific examples.
The specific implementation mode is as follows:
a composition for reducing uric acid is prepared from the following components in parts by mass:
300 parts of silicon dioxide, 500 parts of sodium aluminosilicate 200, 1500 parts of disodium hydrogen phosphate, 60-100 parts of sodium dihydrogen phosphate, 8-12 parts of potassium dihydrogen phosphate, 50-300 parts of sodium carbonate, 500 parts of potassium carbonate 100, 50-150 parts of potassium chloride, 5-10 parts of sodium chloride, 0.4-1.2 parts of sodium hydroxide, 10-15 parts of sodium tetraborate, 5-15 parts of sodium thiosulfate, 1500 parts of xylo-oligosaccharide 200, 2000 parts of sucrose 500, 500 parts of glucose 100 and 1200 parts of purified water.
A method for preparing a composition for reducing uric acid, comprising the steps of:
300 parts of silicon dioxide-containing material, 500 parts of sodium aluminosilicate-containing material, 1500 parts of disodium hydrogen phosphate-containing material, 60-100 parts of sodium dihydrogen phosphate, 8-12 parts of potassium dihydrogen phosphate, 50-300 parts of sodium carbonate, 500 parts of potassium carbonate-containing material, 50-150 parts of potassium chloride, 5-10 parts of sodium chloride, 0.4-1.2 parts of sodium hydroxide, 10-15 parts of sodium tetraborate, 5-15 parts of sodium thiosulfate, 1500 parts of xylo-oligosaccharide-containing material, 500 parts of sucrose-containing material and 500 parts of glucose-containing material are gradually dissolved in 1200 parts of 800-containing material at the temperature of 60-80 ℃ and stirred for 150 minutes to form gel, and then placed at the temperature of 25-35 ℃ for more than 48 hours for later use.
The second embodiment is as follows:
example 1: a composition for reducing uric acid is prepared from the following components in parts by mass:
125 parts of silicon dioxide, 332 parts of sodium aluminosilicate, 1100 parts of disodium hydrogen phosphate, 70 parts of sodium dihydrogen phosphate, 9 parts of potassium dihydrogen phosphate, 225 parts of sodium carbonate, 185 parts of potassium carbonate, 78 parts of potassium chloride, 8 parts of sodium chloride, 0.6 part of sodium hydroxide, 12 parts of sodium tetraborate, 10 parts of sodium thiosulfate, 500 parts of xylo-oligosaccharide, 1500 parts of sucrose, 350 parts of glucose and 1000 parts of purified water.
A method for preparing a composition for reducing uric acid, comprising the steps of:
125 parts of silicon dioxide, 332 parts of sodium aluminosilicate, 1100 parts of disodium hydrogen phosphate, 70 parts of sodium dihydrogen phosphate, 9 parts of potassium dihydrogen phosphate, 225 parts of sodium carbonate, 185 parts of potassium carbonate, 78 parts of potassium chloride, 8 parts of sodium chloride, 0.6 part of sodium hydroxide, 12 parts of sodium tetraborate, 10 parts of sodium thiosulfate, 500 parts of xylo-oligosaccharide, 1500 parts of sucrose and 350 parts of glucose are gradually dissolved in 1000 parts of purified water at 60 ℃ and stirred for 120 minutes to form gel, and the gel is placed for more than 48 hours at 30 ℃ for later use.
Example 2: a composition for reducing uric acid is prepared from the following components in parts by mass:
100 parts of silicon dioxide, 200 parts of sodium aluminosilicate, 800 parts of disodium hydrogen phosphate, 60 parts of sodium dihydrogen phosphate, 8 parts of potassium dihydrogen phosphate, 50 parts of sodium carbonate, 100 parts of potassium carbonate, 50 parts of potassium chloride, 5 parts of sodium chloride, 0.4 part of sodium hydroxide, 10 parts of sodium tetraborate, 5 parts of sodium thiosulfate, 200 parts of xylo-oligosaccharide, 500 parts of sucrose, 100 parts of glucose and 800 parts of purified water.
A method for preparing a composition for reducing uric acid, comprising the steps of:
100 parts of silicon dioxide, 200 parts of sodium aluminosilicate, 800 parts of disodium hydrogen phosphate, 60 parts of sodium dihydrogen phosphate, 8 parts of potassium dihydrogen phosphate, 50 parts of sodium carbonate, 100 parts of potassium carbonate, 50 parts of potassium chloride, 5 parts of sodium chloride, 0.4 part of sodium hydroxide, 10 parts of sodium tetraborate, 5 parts of sodium thiosulfate, 200 parts of xylo-oligosaccharide, 500 parts of sucrose and 100 parts of glucose are gradually dissolved in 800 parts of purified water at 70 ℃ and stirred for 100 minutes to form gel, and the gel is placed for more than 48 hours at 30 ℃ for later use.
Example 3: a composition for reducing uric acid is prepared from the following components in parts by mass:
300 parts of silicon dioxide, 500 parts of sodium aluminosilicate, 1500 parts of disodium hydrogen phosphate, 100 parts of sodium dihydrogen phosphate, 12 parts of potassium dihydrogen phosphate, 300 parts of sodium carbonate, 500 parts of potassium carbonate, 150 parts of potassium chloride, 10 parts of sodium chloride, 1.2 parts of sodium hydroxide, 15 parts of sodium tetraborate, 15 parts of sodium thiosulfate, 1500 parts of xylo-oligosaccharide, 2000 parts of sucrose, 500 parts of glucose and 1200 parts of purified water.
A method for preparing a composition for reducing uric acid, comprising the steps of:
300 parts of silicon dioxide, 500 parts of sodium aluminosilicate, 1500 parts of disodium hydrogen phosphate, 100 parts of sodium dihydrogen phosphate, 12 parts of potassium dihydrogen phosphate, 300 parts of sodium carbonate, 500 parts of potassium carbonate, 150 parts of potassium chloride, 10 parts of sodium chloride, 1.2 parts of sodium hydroxide, 15 parts of sodium tetraborate, 15 parts of sodium thiosulfate, 1500 parts of xylo-oligosaccharide, 2000 parts of sucrose and 500 parts of glucose are gradually dissolved in 1200 parts of purified water at 80 ℃ and stirred for 150 minutes to form gel, and the gel is placed for more than 48 hours at 35 ℃ for later use.
Example 4: a composition for reducing uric acid is prepared from the following components in parts by mass:
300 parts of sodium silicate, 500 parts of potassium silicate, 800 parts of disodium hydrogen phosphate, 60 parts of sodium dihydrogen phosphate, 8 parts of potassium dihydrogen phosphate, 5 parts of sodium carbonate, 100 parts of potassium carbonate, 5 parts of potassium chloride, 5 parts of sodium chloride, 0.4 part of germanium dioxide, 0.5 part of sodium molybdate, 10 parts of sodium tetraborate, 5 parts of sodium thiosulfate, 600 parts of xylo-oligosaccharide, 900 parts of sucrose, 100 parts of glucose and 1000 parts of purified water.
A method for preparing a composition for reducing uric acid, comprising the steps of:
300 parts of sodium silicate, 500 parts of potassium silicate, 800 parts of disodium hydrogen phosphate, 60 parts of sodium dihydrogen phosphate, 8 parts of potassium dihydrogen phosphate, 5 parts of sodium carbonate, 100 parts of potassium carbonate, 5 parts of potassium chloride, 5 parts of sodium chloride, 0.4 part of germanium dioxide, 0.5 part of sodium molybdate, 10 parts of sodium tetraborate, 5 parts of sodium thiosulfate, 600 parts of xylo-oligosaccharide, 900 parts of sucrose and 100 parts of glucose are gradually dissolved in 800 parts of purified water at the temperature of more than 60 ℃ to be stirred for 50 minutes to form gel, and the gel is placed for 48 hours at the temperature of 25 ℃ for later use.
The following embodiment of the present invention describes a specific example of a patient with hyperuricemia, so that those skilled in the art can clearly understand the technical solutions and technical effects in the present application
Example (b): clinical trial
Test time: the test started at 26.11.2019 and ended at 27.12.2019.
In the test, 5 hyperuricemia patients, 3 men and 2 women, are selected, and after taking the invention for 30 days, under the condition of keeping the original dietary habits unchanged, all indexes of all patients are recorded and counted, and are compared and analyzed.
The taking method comprises the following steps: the finished product of the invention is taken and dropped into water for drinking every day, 2-4 drops are taken every day, and 1 month is a treatment course.
Detection indexes are as follows: the weight and the blood uric acid value of a patient are respectively detected within 1 day before taking, 7 days after taking, 15 days after taking and 30 days after taking, the uric acid is quantified for 24 hours, and the urine pH value is detected within 7 days before taking and 30 days after taking, and the detection results are as follows:
as can be seen from the above table, for the patient with high uric acid, under the condition that the original dietary habit is not changed, the blood uric acid content of the patient is gradually reduced along with the increase of the taking time after the patient takes the traditional Chinese medicine composition, the urine pH is gradually increased, and the uric acid excretion amount in 24 hours is slightly increased, but is not obvious, after the patient orally takes the traditional Chinese medicine composition for 7 days, the arthralgia is greatly relieved, the indexes are obviously improved after the traditional Chinese medicine composition is taken for more than 15 days, the effect is better after the traditional Chinese medicine composition is taken for a long time, and the traditional Chinese medicine composition is non-toxic and harmless, has no adverse effect on the human body, and is low in cost.
The above description is only a preferred embodiment of the present invention, and the protection scope of the present invention is not limited to the above embodiments, and all technical solutions belonging to the idea of the present invention belong to the protection scope of the present invention. It should be noted that modifications and embellishments within the scope of the invention may occur to those skilled in the art without departing from the principle of the invention, and are considered to be within the scope of the invention.
Claims (4)
1. The composition for reducing uric acid is characterized by being prepared from the following components in parts by mass:
300 parts of silicon dioxide, 500 parts of sodium aluminosilicate 200, 1500 parts of disodium hydrogen phosphate, 60-100 parts of sodium dihydrogen phosphate, 8-12 parts of potassium dihydrogen phosphate, 50-300 parts of sodium carbonate, 500 parts of potassium carbonate 100, 50-150 parts of potassium chloride, 5-10 parts of sodium chloride, 0.4-1.2 parts of sodium hydroxide, 10-15 parts of sodium tetraborate, 5-15 parts of sodium thiosulfate, 1500 parts of xylo-oligosaccharide 200, 2000 parts of sucrose 500, 500 parts of glucose 100 and 1200 parts of purified water.
2. Composition useful for reducing uric acid according to claim 1, characterized in that: the composition is prepared from the following components in parts by mass:
125 parts of silicon dioxide, 332 parts of sodium aluminosilicate, 1100 parts of disodium hydrogen phosphate, 70 parts of sodium dihydrogen phosphate, 9 parts of potassium dihydrogen phosphate, 225 parts of sodium carbonate, 185 parts of potassium carbonate, 78 parts of potassium chloride, 8 parts of sodium chloride, 0.6 part of sodium hydroxide, 12 parts of sodium tetraborate, 10 parts of sodium thiosulfate, 500 parts of xylo-oligosaccharide, 1500 parts of sucrose, 350 parts of glucose and 1000 parts of purified water.
3. A method for preparing a composition for lowering uric acid as defined in claim 1, wherein the composition comprises: the method comprises the following steps:
300 parts of silicon dioxide-containing material, 500 parts of sodium aluminosilicate-containing material, 1500 parts of disodium hydrogen phosphate-containing material, 60-100 parts of sodium dihydrogen phosphate, 8-12 parts of potassium dihydrogen phosphate, 50-300 parts of sodium carbonate, 500 parts of potassium carbonate-containing material, 50-150 parts of potassium chloride, 5-10 parts of sodium chloride, 0.4-1.2 parts of sodium hydroxide, 10-15 parts of sodium tetraborate, 5-15 parts of sodium thiosulfate, 1500 parts of xylo-oligosaccharide-containing material, 500 parts of sucrose-containing material and 500 parts of glucose-containing material are gradually dissolved in 1200 parts of 800-containing material at the temperature of 60-80 ℃ and stirred for 150 minutes to form gel, and then placed at the temperature of 25-35 ℃ for more than 48 hours for later use.
4. The method for preparing a composition useful for lowering uric acid according to claim 3, characterized in that: the method comprises the following steps:
125 parts of silicon dioxide, 332 parts of sodium aluminosilicate, 1100 parts of disodium hydrogen phosphate, 70 parts of sodium dihydrogen phosphate, 9 parts of potassium dihydrogen phosphate, 225 parts of sodium carbonate, 185 parts of potassium carbonate, 78 parts of potassium chloride, 8 parts of sodium chloride, 0.6 part of sodium hydroxide, 12 parts of sodium tetraborate, 10 parts of sodium thiosulfate, 500 parts of xylo-oligosaccharide, 1500 parts of sucrose and 350 parts of glucose are gradually dissolved in 1000 parts of purified water at 60 ℃ and stirred for 120 minutes to form gel, and the gel is placed for more than 48 hours at 30 ℃ for later use.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010665328.0A CN113908173A (en) | 2020-07-11 | 2020-07-11 | Composition for reducing uric acid and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010665328.0A CN113908173A (en) | 2020-07-11 | 2020-07-11 | Composition for reducing uric acid and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113908173A true CN113908173A (en) | 2022-01-11 |
Family
ID=79232374
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010665328.0A Pending CN113908173A (en) | 2020-07-11 | 2020-07-11 | Composition for reducing uric acid and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113908173A (en) |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1739574A (en) * | 2005-09-02 | 2006-03-01 | 颜怀玮 | Dietotherapeutic nutrient for preventing and treating gout and its prepn process |
| JP2011016792A (en) * | 2009-06-12 | 2011-01-27 | Lion Corp | Uric acid level lowering composition |
| CN107149065A (en) * | 2016-03-03 | 2017-09-12 | 北京圣岩共赢生物科技有限公司 | A kind of electrolyte energy drink |
| CN107937322A (en) * | 2018-01-09 | 2018-04-20 | 倪同艳 | A kind of alkaline medium and its application |
| CN109820070A (en) * | 2019-04-02 | 2019-05-31 | 河北医科大学第三医院 | A kind of formula tea and preparation method thereof reducing blood uric acid |
| CN110353103A (en) * | 2019-07-24 | 2019-10-22 | 倪同艳 | A kind of additive and preparation method thereof reducing forage protein or energy |
| CN110840937A (en) * | 2019-12-11 | 2020-02-28 | 安徽赐缘生物科技有限公司 | Traditional Chinese medicine extract for reducing uric acid and preparation method thereof |
-
2020
- 2020-07-11 CN CN202010665328.0A patent/CN113908173A/en active Pending
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1739574A (en) * | 2005-09-02 | 2006-03-01 | 颜怀玮 | Dietotherapeutic nutrient for preventing and treating gout and its prepn process |
| JP2011016792A (en) * | 2009-06-12 | 2011-01-27 | Lion Corp | Uric acid level lowering composition |
| CN107149065A (en) * | 2016-03-03 | 2017-09-12 | 北京圣岩共赢生物科技有限公司 | A kind of electrolyte energy drink |
| CN107937322A (en) * | 2018-01-09 | 2018-04-20 | 倪同艳 | A kind of alkaline medium and its application |
| CN109820070A (en) * | 2019-04-02 | 2019-05-31 | 河北医科大学第三医院 | A kind of formula tea and preparation method thereof reducing blood uric acid |
| CN110353103A (en) * | 2019-07-24 | 2019-10-22 | 倪同艳 | A kind of additive and preparation method thereof reducing forage protein or energy |
| CN110840937A (en) * | 2019-12-11 | 2020-02-28 | 安徽赐缘生物科技有限公司 | Traditional Chinese medicine extract for reducing uric acid and preparation method thereof |
Non-Patent Citations (2)
| Title |
|---|
| 梁蓉等: "《内科学》", 31 December 2018, 中国医药科技出版社, pages: 370 - 372 * |
| 薛耀明等: "《痛风防治实用指导》", 30 April 2018, 河南科学技术出版社, pages: 3 - 5 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP3048380B2 (en) | Antihypertensive agent and its production method | |
| KR101870846B1 (en) | Multi-functional composition and preparation method and application thereof | |
| CN103142655B (en) | Composite probiotics for treating podagra and preparation method thereof | |
| CN111887370A (en) | Uric acid-reducing ocean fish oligopeptide-chitosan oligosaccharide solid beverage | |
| WO2004078139A2 (en) | Therapeutic compositions | |
| CN110680906B (en) | Glucosamine bone glue peptide calcium granules | |
| CN114271502A (en) | Clam peptide compound for protecting cardiovascular system and kidney and application thereof | |
| CN102987206A (en) | Composition capable of reducing blood glucose | |
| STERN | Severe lithium chloride poisoning with complete recovery: report of case | |
| CN114259507A (en) | Application of Klebsiella minutissima in preparing medicine for treating and/or preventing hyperuricemia-related diseases | |
| CN113908173A (en) | Composition for reducing uric acid and preparation method thereof | |
| CN110742902A (en) | Lithium ion composition and application thereof | |
| Purohit et al. | Metabolic disorders in the parturient buffalo | |
| CN116286534A (en) | Lactobacillus plantarum for relieving hyperuricemia, and compound and application thereof | |
| CN110934296A (en) | Composition with effect of preventing and treating diabetes and application thereof | |
| CN115088747B (en) | Composition for preparing low GI food and application thereof | |
| CN114848699B (en) | Composition with uric acid reducing effect and preparation method and application thereof | |
| CN115137068A (en) | Composition for reducing uric acid and application thereof | |
| CN109223740A (en) | A kind of application of tromethamine acylate | |
| CN108379455B (en) | Uric acid reducing composition | |
| CN108576735B (en) | Jelly with effect of inhibiting starch decomposition and preparation method thereof | |
| TW202034790A (en) | Bitter gourd peptide composition | |
| McCANN et al. | STUDIES OF DIABETES MELLITUS: II. RESULTS OF TREATMENT BY DIET ADJUSTMENT WITH REFERENCE TO MAINTENANCE REQUIREMENT AND THE KETOGENIC-ANTIKETOGENIC BALANCE | |
| JP5019708B2 (en) | Composition for the treatment and prevention of diabetes | |
| CN109864036A (en) | A kind of calf dietetic diarrhea treatment method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |